Two gene editing firms unveil cancer drug pacts as ASCO comes to a close – Boston Business Journal

Posted: June 6, 2017 at 4:44 pm

Two gene editing firms unveil cancer drug pacts as ASCO comes to a close Boston Business Journal The research drew blowback from Intellia, which said that the claim about off-target effects lacked evidence and was based on a sample. In addition to Intellia and CRISPR Therapeutics, the other leading gene-editing firm is Cambridge-based Editas ... and more »

More here:
Two gene editing firms unveil cancer drug pacts as ASCO comes to a close - Boston Business Journal

Recommendation and review posted by Guinevere Smith